Our nose holds antibiotic to fight 'superbugs'

Image
Press Trust of India Berlin
Last Updated : Jul 31 2016 | 5:42 PM IST
A bacteria which colonises the human nose produces a previously unknown antibiotic that may combat multiresistant pathogens such as MRSA.
Scientists at the University of Tubingen and the German Centre for Infection Research (DZIF) discovered that Staphylococcus lugdunensis in our nose produces the antibiotic.
As tests on mice have shown, the substance which has been named Lugdunin is able to combat multiresistant pathogens, where many classic antibiotics have become ineffective.
Infections caused by antibiotic-resistant bacteria - like the pathogen Staphylococcus aureus (MRSA) which colonises on human skin - are among the leading causes of death worldwide.
The natural habitat of harmful Staphylococcus bacteria is the human nasal cavity.
In their experiments, researchers observed that Staphylococcus aureus is rarely found when Staphylococcus lugdunensis is present in the nose.
"Normally antibiotics are formed only by soil bacteria and fungi. The notion that human microflora may also be a source of antimicrobial agents is a new discovery," said Professor Andreas Peschel, from Interfaculty Institute for Microbiology and Infection Medicine Tubingen (IMIT).
In future studies, scientists will examine whether Lugdunin could actually be used in therapy. One potential use is introducing harmless Lugdunin-forming bacteria to patients at risk from MRSA as a preventative measure.
Researchers closely examined the structure of Lugdunin and discovered that it consists of a previously unknown ring structure of protein blocks and thus establishes a new class of materials.
Antibiotic resistance is a growing problem for physicians.
As many of the pathogens are part of human microflora on skin and mucous membranes, they cannot be avoided.
Particularly for patients with serious underlying illnesses and weakened immune systems they represent a high risk - these patients are easy prey for the pathogens.
The research was published in the journal Nature.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 31 2016 | 5:42 PM IST

Next Story